NYXOAH SA (NYXH) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:NYXH • BE0974358906

4.59 USD
-0.08 (-1.71%)
Last: Feb 5, 2026, 04:30 PM

NYXH Key Statistics, Chart & Performance

Key Statistics
Market Cap197.51M
Revenue(TTM)5.64M
Net Income(TTM)-83.57M
Shares43.03M
Float26.86M
52 Week High11.87
52 Week Low4.35
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-2.65
PEN/A
Fwd PEN/A
Earnings (Next)05-12
IPO2020-09-18
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
NYXH short term performance overview.The bars show the price performance of NYXH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

NYXH long term performance overview.The bars show the price performance of NYXH in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of NYXH is 4.59 USD. In the past month the price decreased by -8.38%. In the past year, price decreased by -56.89%.

NYXOAH SA / NYXH Daily stock chart

NYXH Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

NYXH Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NYXH. NYXH has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NYXH Financial Highlights

Over the last trailing twelve months NYXH reported a non-GAAP Earnings per Share(EPS) of -2.65. The EPS decreased by -30.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -89.29%
ROE -164.01%
Debt/Equity 0.4
Chartmill High Growth Momentum
EPS Q2Q%-27.02%
Sales Q2Q%55.77%
EPS 1Y (TTM)-30.42%
Revenue 1Y (TTM)10.96%

NYXH Forecast & Estimates

14 analysts have analysed NYXH and the average price target is 11.05 USD. This implies a price increase of 140.8% is expected in the next year compared to the current price of 4.59.

For the next year, analysts expect an EPS growth of -21.84% and a revenue growth 48.25% for NYXH


Analysts
Analysts81.43
Price Target11.05 (140.74%)
EPS Next Y-21.84%
Revenue Next Year48.25%

NYXH Ownership

Ownership
Inst Owners17.27%
Ins Owners19.98%
Short Float %0.83%
Short Ratio4.79

NYXH Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.02188.146B
ISRG INTUITIVE SURGICAL INC47.95169.625B
SYK STRYKER CORP23.97137.924B
BSX BOSTON SCIENTIFIC CORP22.17111.924B
BDX BECTON DICKINSON AND CO13.7559.33B
IDXX IDEXX LABORATORIES INC43.4451.339B
EW EDWARDS LIFESCIENCES CORP26.3846.291B
RMD RESMED INC21.7538.394B
GEHC GE HEALTHCARE TECHNOLOGY16.3937.64B
DXCM DEXCOM INC27.7627.621B

About NYXH

Company Profile

NYXH logo image Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Company Info

NYXOAH SA

Rue Edouard Belin 12

Mont-Saint-Guibert BRABANT-WALLON BE

CEO: Olivier Taelman

Employees: 184

NYXH Company Website

NYXH Investor Relations

Phone: 3226121755

NYXOAH SA / NYXH FAQ

What does NYXH do?

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.


Can you provide the latest stock price for NYXOAH SA?

The current stock price of NYXH is 4.59 USD. The price decreased by -1.71% in the last trading session.


What is the dividend status of NYXOAH SA?

NYXH does not pay a dividend.


What is the ChartMill technical and fundamental rating of NYXH stock?

NYXH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the number of employees for NYXOAH SA?

NYXOAH SA (NYXH) currently has 184 employees.


What is NYXOAH SA worth?

NYXOAH SA (NYXH) has a market capitalization of 197.51M USD. This makes NYXH a Micro Cap stock.